Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
7.80
-0.16 (-2.01%)
Oct 29, 2025, 1:11 PM EDT - Market open
Omeros Employees
Omeros had 202 employees as of December 31, 2024. The number of employees increased by 4 or 2.02% compared to the previous year.
Employees
202
Change (1Y)
4
Growth (1Y)
2.02%
Revenue / Employee
n/a
Profits / Employee
-$606,307
Market Cap
530.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | 277 | 19 | 7.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OMER News
- 11 days ago - Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting - Seeking Alpha
- 13 days ago - Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case - Seeking Alpha
- 13 days ago - Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group - Business Wire
- 13 days ago - Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Benzinga
- 14 days ago - Can OMER stock retain Novo Nordisk driven gains over the long-term? - Invezz
- 14 days ago - Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug - WSJ
- 14 days ago - Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push - Reuters
- 14 days ago - Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906) - GlobeNewsWire